



June 16, 2016

CUSTOMS MEMORANDUM CIRCULAR NO. 84 - 2014

**TO:** All Deputy Commissioners

All Directors and Division Chiefs All District / Port Collectors And Others Concerned

SUBJECT: FDA Circular No. 2016-006 / New Format of License to

Operate (LTO) for Establishments Regulated by the FDA

Attached is the letter dated June 7, 2016 of Ms. Maria Lourdes C. Santiago, MSc., MM, OIC-Director General, Food and Drug Administration (FDA), furnishing this Bureau with a copy of FDA Circular No. 2016-006 entitled: "New Format of License to Operate (LTO) for Establishments Regulated by the FDA"

For your information and guidance.

Please confirm the dissemination of this circular throughout your offices within fifteen (15) days from receipt hereof.

ALBERTO D. LINA

Commissioner

ALBERTO D. LINA
Commissioner
16-03580

JUN 2 0 2016

06-002





# Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



07 June 2016

Mr. ALBERTO D. LINA

Commissioner
Bureau of Customs
G/F, OCOM Building
Port Area, Manila

Dear Commissioner Lina:

FDA" (please see attached).

Warm greetings from the Food and Drug Administration (FDA)!



The FDA is pleased to inform your good office of the new format of License To Operate (LTO) we will soon use. The LTO will contain essential information on the first and second pages to align with the provisions of FDA Circular No. 2016-006, "New Format of License To Operate (LTO) for Establishments Regulated by the

We earnestly request that this guideline be disseminated within your agency for the information, reference and guidance of all concerned.

Thank you for the kind attention and your usual support and cooperation.


Very truly yours,

MARIA LOURDES C. SANTIAGO, MSc., MM OIC, Director General

Attachment: As stated









## Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



07 JUN 2016

FDA CIRCULAR No. \_\_\_\_\_2016 -006

TO

ALL ESTABLISHMENTS REGULATED BY THE

FOOD AND DRUG ADMINISTRATION (FDA)
AND OTHER CONCERNED STAKEHOLDERS

SUBJECT:

New Format of License to Operate (LTO) for

Establishments Regulated by the FDA

#### 1. BACKGROUND

Part of the continuous quality improvement activities of the Food and Drug Administration (FDA) as an ISO certified institution is to enhance, upgrade and strengthen its processes by establishing an effective and efficient Quality Management System (QMS) in place. The FDA has streamlined its requirements for ease of doing business and improved the quality of its services in order to address the needs of its clients.

With the issuance of Administrative Order (A.O.) No. 2016-0003 entitled "Guidelines on the Unified Licensing Requirements and Procedures of the Food and Drug Administration," a new LTO format for establishments regulated by the FDA is deemed necessary.

## 2. DETAILS

#### 2.1. LICENSE TO OPERATE

The LTO shall reflect the following information:

- 2.1.1. The first page of the new LTO format shall reflect only the following data:
  - 2.1.1.1. Type of application
  - 2.1.1.2. Primary activity(ies)
  - 2.1.1.3. Name of establishment
  - 2.1.1.4. Address of the establishment
  - 2.1.1.5. Name of owner
  - 2.1.1.6. LTO number and validity
  - 2.1.1.7. Payment details (date and amount)
- 2.1.2. The second page of the new LTO format shall contain the minimum data:







- 2.1.2.1. For drugs manufacturers, list of key personnel (e.g., quality control/quality assurance manager, production head, pharmacist (whenever applicable) and authorized person for product batch release) in accordance with the requirements of current regulations on Good Manufacturing Practices (GMP); and
- 2.1.2.2. Additional activity(ies) (whenever applicable)
- 2.1.3. The second page should be made readily available upon request by stakeholders and authorities.
- 2.1.4. A new LTO shall be issued incorporating any variation to the original LTO, regardless of its validity.

#### 3. REPEALING CLAUSE

This Circular repeals any inconsistent previous issuance, including FDA Circular No. 2015-006 known as "New LTO Format for Drug Establishments Following Administrative Order No. 2013-0034."

## 4. EFFECTIVITY

This Circular shall take effect immediately.

MARIA LOURDES C. SANTIAGO, MSc., MM OIC, Director General